Oramed Pharmaceuticals Stock Cash And Equivalents
| ORMP Stock | 8.63 0.02 0.23% |
Oramed Pharmaceuticals fundamentals help investors to digest information that contributes to Oramed Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Oramed Stock. The fundamental analysis module provides a way to measure Oramed Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Oramed Pharmaceuticals stock.
Oramed |
Oramed Pharmaceuticals Company Cash And Equivalents Analysis
Oramed Pharmaceuticals' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Oramed Pharmaceuticals Cash And Equivalents | 26.19 M |
Most of Oramed Pharmaceuticals' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Oramed Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, Oramed Pharmaceuticals has 26.19 M in Cash And Equivalents. This is much higher than that of the sector and significantly higher than that of the Cash And Equivalents industry. The cash and equivalents for all Israel stocks is notably lower than that of the firm.
Oramed Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Oramed Pharmaceuticals' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Oramed Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Oramed Pharmaceuticals by comparing valuation metrics of similar companies.Oramed Pharmaceuticals is currently under evaluation in cash and equivalents category among its peers.
Oramed Fundamentals
| Return On Equity | -78.51 | |||
| Return On Asset | -26.77 | |||
| Operating Margin | (584.92) % | |||
| Current Valuation | 156.33 M | |||
| Shares Outstanding | 17.38 M | |||
| Price To Book | 866.13 X | |||
| Revenue | 2.64 M | |||
| Gross Profit | 2.54 M | |||
| EBITDA | (15.43 M) | |||
| Net Income | (15 M) | |||
| Cash And Equivalents | 26.19 M | |||
| Cash Per Share | 1.51 X | |||
| Current Ratio | 5.10 X | |||
| Book Value Per Share | 1.24 X | |||
| Cash Flow From Operations | (14.32 M) | |||
| Earnings Per Share | (0.87) X | |||
| Number Of Employees | 10 | |||
| Beta | 1.23 | |||
| Market Capitalization | 189.3 M |
About Oramed Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Oramed Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oramed Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oramed Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Oramed Stock
When determining whether Oramed Pharmaceuticals is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Oramed Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Oramed Pharmaceuticals Stock. Highlighted below are key reports to facilitate an investment decision about Oramed Pharmaceuticals Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oramed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Oramed Stock refer to our How to Trade Oramed Stock guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.